30.05.2018 22:05:00

Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference

BOULDER, Colo., May 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2018 Global Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

Event:

Jefferies 2018 Global Healthcare Conference

Presenter:

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:

Wednesday, June 6, 2018

Time:

2 p.m. Eastern Time

Webcast:

http://wsw.com/webcast/jeff113/arry/

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics). For more information on Array, please go to www.arraybiopharma.com.

CONTACT:       
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-jefferies-2018-global-healthcare-conference-300655974.html

SOURCE Array BioPharma

Nachrichten zu Array BioPharma Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Array BioPharma Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!